Molecular Profiling of Odontogenic Tumors – Pilot Study

Download Article

Sibel Elif Gültekin1 / Burcu Sengüven1 / Reem Aziz2 / Carina Heydt2 / Reinhard Buettner2

1Gazi University Faculty of Dentistry, Department of Oral Pathology, Ankara, Turkey
2University of Cologne, Faculty of Medicine, Department of Pathology, Cologne, Germany


Background/Aim: In the pathogenesis of odontogenic tumors which arise from the rests of the dental apparatus in the jaw, several molecular pathways have been shown to play critical roles such as genetic alterations in the hedgehog, BRAF/Ras/MAPK, epidermal growth factor receptor. Next generation genomic sequencing has identified gene mutations in many different tumors. Materials and Methods: Here we report four types of odontogenic tumor including six cases in which five had mutation according to next generation sequencing analysis from archival paraffin blocks that diagnosed previously as ameloblastoma (solid), amloblastoma (unicystic-mural), ameloblastic fibroma, squamous odontogenic tumor, and adenomatoid odontogenic tumor. Results: All ameloblastomatic tumors were shown BRAF mutation and adenomatoid odontogenic tumors were KRAS mutation. Conclusion: This evidence may highlight the poorly understood pathogenesis of odontogenic tumors. Further comparisons need to be made with other benign and malignant odontogenic tumors so that unique odontogenic features may be found.

Keywords: Odontogenic Tumors; Next Generation Sequencing; Mutation


  1. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumors. Pathology and Genetics. Head and Neck Tumours. Lyon: IARC Press; 2005.
  2. Kurppa KJ, Caton J, Morgan RP, Ristimaki A, Ruhin B, Kelloski J et al. High Frequency of BRAF V600E mutations in aamelobastoma. J Pathol, 2014;232:492-498.
  3. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res, 2014;205517-5526.[Web of Science]
  4. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet, 2014;46:722-725.[Crossref][Web of Science]
  5. Brown NA, Betz BL. Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomark Cancer, 2015;7:19-24.
  6. Heikinheimo K, Kurppa KJ, Elenius K. Novel Targets for the Treatment of Ameloblastoma. J Dent Res, 2015;94:237-240.[Web of Science][Crossref]
  7. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet, 2012;44:1104-1110.[Web of Science][Crossref]
  8. Gomes CC, Diniz MG, Gomez RS. Progress towards personalized medicine for ameloblastoma. Comment on J Pathol, 2014;232:492-498.
  9. Oikonomou E, Koustas E, Goulielmaki M, Pintzas A. BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications. Oncotarget, 2014;5:11752-1177.[Crossref]
  10. Gomes CC, de Sousa SF, de Menezes GH, Duarte AP, Pereira Tdos S, Moreira RG et al. Recurrent KRAS G12V pathogenic mutation in adenomatoid odontogenic tumours. Oral Oncol, 2016;56:e3-5.[Web of Science]
  11. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res, 1989;49:4682-4689.
Citation Information: Balkan Journal of Dental Medicine, ISSN (Online) 2335-0245, DOI: Export Citation